EFD were all significant predictors (all p values <0.001). ADT was also a significant predictor of post-RP EFD, with A group having a mean EFD score 4.0 points lower than N group (p¼0.002). When assessing men with only good baseline EF (EFD!24), the percentage of men with good EF was similar: A 78% v N 79%, p¼0.72. At follow-up, A group had a significantly lower percentage reporting good EF compared to N group: A 19% v N 41%, RR¼0.45, 95% CI: 0.23-0.85 p¼0.01. Pre-RP, both groups reported a low % of baseline severe ED: A 2%; N 3%, p¼0.86. At follow-up, severe ED was more common in A group: A 44% vs. N 24%, RR¼1.97, 95% CI: 1.28-2.59, p¼0.01. On MVA, in this subcohort, ADT was a significant predictor post-RP EFD, A group having a mean EFD score 4.7 points lower than N group (p¼0.001).CONCLUSIONS: ADT pre-RP leads to worse EFR. While neoadjuvant ADT is currently being explored as strategy for RP patients with high-risk disease, it is important that oncologists appreciate he consequences of this on EFR and should communicate this to patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.